UBS Group
LMDXW

UBS Group’s LumiraDx Limited Warrant LMDXW Stock Holding History

UBS Group’s Portfolio LMDXW Stock Details LMDXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,276
Closed -$1K – 11391
2022
Q3 		$1K Hold
6,276
– – ﹤0.01% 10128
2022
Q2 		$6K Buy
6,276
+2,895
+86% +$2.5K ﹤0.01% 8763
2022
Q1 		$3K Buy
3,381
+1,393
+70% +$1.79K ﹤0.01% 9524
2021
Q4 		$4K Buy
+1,988
New +$3.21K ﹤0.01% 9577

Other funds holding LMDXW

CH
CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return

UBS Group's LMDXW Position: Q4 2022 in Review

UBS Group sold out of LumiraDx Limited Warrant (LMDXW) in Q4 2022, closing a stake of 6,276 shares — an estimated $1K sold.

UBS Group first reported a position in LMDXW in Q4 2021 and held it in 4 quarters. The position peaked at $6K in Q2 2022. 17 funds tracked by Wall St. Rank hold LMDXW as of Q4 2022.

  • UBS Group reported no remaining LumiraDx Limited Warrant position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 6,276 LumiraDx Limited Warrant shares in Q4 2022, an estimated $1K.
  • UBS Group first reported a position in LumiraDx Limited Warrant in Q4 2021 and held it in 4 quarters.
  • UBS Group's LumiraDx Limited Warrant position peaked at $6K in Q2 2022.
  • 17 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.